National Cancer Policy Forum Workshop Ensuring Patient Access to Cancer Drugs

The Keck Center of the National Academies 500 Fifth Street, NW - Room 100 Washington, DC 20001

	June 9, 2014
7:30 am	Registration and Breakfast
8:00 am	Welcome from the IOM's National Cancer Policy Forum
	Michael Caligiuri, Ohio State University Comprehensive Cancer Center
	Chair, National Cancer Policy Forum
	Overview of the Workshop
	Peter Bach, Memorial Sloan-Kettering Cancer Center
	Planning Committee Chair
8:15am	Session 1: Trends in Oncology Care
	Moderator: Barry Fortner, ION Solutions
	Escalating drug prices:
	Kalipso Chalkidou, NICE International (via webex)
	Consolidation of practices into hospital partnerships/changing landscape of
	oncology practice
	Bruce Gould, Community Oncology Alliance
	The Financial Toxicity of Cancer Treatment: Can Patients Cope with Costs?
	 Yousuf Zafar, Duke University Medical School, Duke Cancer Center
	Drug shortages
	Peyton Howell, Amerisource Bergen
	CMS reimbursement policies in oncology
	Marc Hartstein, Center for Medicare & Medicaid Services
	Panel Discussion
10.45	
10:45am	Break
11:00am	Keynote Address- Pharma pricing practices and the case for market self-correction
	Alex Bastian, GfK Custom Research, LLC
11:30 am	Lunch
12:15 pm	Session 2: Paradoxes of Cancer Drug Reimbursement
	Moderator: Jeffery Ward, Swedish Cancer Institute
	I .

	Brand name drugs v. generics
	Jeffrey Peppercorn, Duke University Medical School
	Oral vs. IV drugs
	Lee Newcomer, United Health Group
	340b vs. everyone else
	Rena Conti, University of Chicago
	Private practice v. hospital-based care
	Eric Hammelman, Avalere Health
	Variable co-insurance and premiums
	Michael Kolodziej, Aetna
	Panel Discussion
2:45 pm	Break
3:00 pm	Session 3: Value and Policy Options
	Moderator: Scott Ramsey, Fred Hutchinson Cancer Center
	The Patient Perspective
	Shelley Fuld Nasso, National Coalition for Cancer Survivorship
	Value based insurance design
	Mark Fendrick, University of Michigan Center for Value Based Insurance
	Design
	Bundling of payments
	Thomas Feeley, MD Anderson Cancer Center
	Value-based drug pricing
	Patricia Danzon, The Wharton School, University of Pennsylvania Learne from the Health Evidence Province Commission, Oracon Health Authority
	Lessons from the Health Evidence Review Commission, Oregon Health Authority
	Kevin Olson, Providence Cancer Center
	Panel Discussion
5.20	Addition
5:30 pm	Adjourn